Navigation Links
Neurocrine Biosciences Reports Third Quarter 2008 Results
Date:10/28/2008

is symptoms using several different scales for endometriosis pain. The 6-month results from this study, together with data from the other Phase II studies, will be the basis for securing agreement on a registration plan with the Food and Drug Administration (FDA).

The Company is also currently conducting two additional randomized placebo-controlled Phase II clinical trials. The clinical endpoints for both of these trials are a reduction in pelvic pain associated with endometriosis, utilizing a scale proposed by the FDA. The first Phase II trial includes our selected commercial formulation tablet in two doses, (150 mg and 250 mg); this trial has completed randomization in 155 patients. The Company expects topline results from the first three months of treatment in the first quarter of 2009. The second trial is a four arm comparator trial of two doses of elagolix (150 mg and 250 mg), placebo or leuprolide depot. This trial is being conducted in Central and Eastern Europe. Topline data from this 3-month double-blind trial of approximately 180 patients should be available at the end of the first half of 2009.

Neurocrine is also investigating the potential of certain GnRH antagonists in treating other hormone-dependent diseases in Men's and Women's Health.

Corticotropin Releasing Factor (CRF1) Receptor Antagonists for Anxiety/Depression and IBS

The CRF collaboration between Neurocrine and GSK has identified multiple unique high affinity and selective antagonists for the CRF1 receptor that are currently in clinical development for mood disorders and irritable bowel syndrome (IBS). There are currently three distinct CRF compounds in clinical development that have arisen out of the GSK collaboration. The compound (876008) is in a Phase II "proof of concept" trial to evaluate its safety and efficacy in patients with IBS. Approximately 130 patients meeting established diagnostic criteria for IBS have been entered into this cross-over design trial.
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Webcast Alert: Neurocrine Announces 3Q 08 Financial Results
2. Neurocrine Biosciences to Present at the Oppenheimer 19th Annual Healthcare Conference
3. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2008 Financial Results
4. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
5. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
6. Neurocrine Biosciences Reports Second Quarter 2008 Results
7. Neurocrine Biosciences Announces Conference Call and Webcast To Present Second Quarter 2008 Financial Results
8. Neurocrine Biosciences to Present at the 2008 Citi Investment Research Global Health Care Conference
9. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2008 Financial Results
10. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2007 Financial Results
11. Neurocrine Announces Appointment of Kevin Gorman, Ph.D., as President and Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... St. Louis, MO (PRWEB) May 21, 2015 ... that assesses the safety and efficacy of pharmaceutical products ... Access Drive Maryland Heights, MO 63043, a 50,000 sq. ... their current location, to enable strategic growth. Facility renovations ... offices to the new space will occur in September. ...
(Date:5/21/2015)... 2015 uBiome, the leading startup ... with PicnicHealth, a healthcare company that collects and ... Inflammatory Bowel Disease (IBD) will receive a complementary ... research kit. Both companies were funded by Y ... For more information on this partnership and how ...
(Date:5/21/2015)... May 21, 2015 Patent Offering, The ... for diagnostic or therapeutic imaging within a body lumen ... an endoscope having a low cost, single-use disposable illumination ... date was October 18, 2013 and the patent approval ... enables the physician to customize the lighting and magnification ...
(Date:5/21/2015)... 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (TSX.V: ... company focused on the development of autologous cell ... the International Society for Cellular Therapy (ISCT) on ... currently in a Phase 1/2 clinical trial.  The ... from 5:30 PM to 7:00 PM local time, ...
Breaking Biology Technology:Seventh Wave Laboratories Purchases Building for Expansion, Upcoming Move 2Seventh Wave Laboratories Purchases Building for Expansion, Upcoming Move 3uBiome Partners with PicnicHealth 2uBiome Partners with PicnicHealth 3IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 2IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 3RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3
... the viability of Embryonic Stem Cells is an Illusion. Repair (Adult) ... treated all over the world, that it will be impossible for embryonic ... ever. , ... Bangkok (PRWEB) March 12, 2009 -- Don Margolis, the ...
... AURORA, Ontario, March 12 Helix BioPharma Corp. (TSX, ... 20-F has been declared effective by the U.S. Securities ... registered with the SEC pursuant to Section 12(g) of ... of Helix,s shares in the United States allows its ...
... ATLANTA, March 12 GeoVax Labs, Inc. (OTC Bulletin ... of an HIV/AIDS vaccine, today announced its financial results ... 2008, and provided a summary of recent operational highlights ... loss of $1,039,217 for the fourth quarter ended December ...
Cached Biology Technology:Repair Stem Cell Institute Weighs in on Reversal of Embryonic Stem Cell Policy 2Helix BioPharma Form 20-F Registration Statement Declared Effective by SEC 2Helix BioPharma Form 20-F Registration Statement Declared Effective by SEC 3GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results 2GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results 3GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results 4GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results 5GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results 6GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results 7GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results 8GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results 9GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results 10GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results 11
(Date:4/13/2015)... , April 13, 2015 ... Research, "Global Biometrics Market Forecast & Opportunities, 2020", the ... CAGR of around 14% till 2020. The biometrics ... large scale implementation and review of biometric management ... of new products with greater efficiency, are resulting ...
(Date:4/9/2015)... , April 9, 2015 Synaptics Inc. (NASDAQ: ... solutions, announced today that it will report financial results ... April 23, 2015, after the close of market. The ... and investors at 2:00 p.m. PT (5:00 p.m. ET), ... To participate on the live call, analysts and ...
(Date:4/2/2015)... April 2, 2015 In ... by far outperforms the strongest competitors, showing outstanding ... accuracy, the system is capable of a throughput ... proves up to be ten times faster than ... runner-up performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
Breaking Biology News(10 mins):Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2Synaptics to Report Third Quarter Results on April 23 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... scholar, Fernando Rios loved science and computer programming equally. ... in physics from Canada,s University of Waterloo went ... Department of Scientific Computing at Florida State University, ... new undergraduate program of computational sciences in fall 2010. ...
... each other, according to research by Sarah Leclaire from the ... Sabatier in France and her team. Their work also suggests ... of individual birds, and could be used in mate choice ... is published in the July issue of Springer,s journal ...
... Hopkins University School of Medicine have developed a technique ... using nanoparticles that can be freeze-dried and stored for ... particles may obviate the need for virus-mediated gene therapy, ... appears in the August issue of Biomaterials . ...
Cached Biology News:New software aids fight against nitrates in Florida's groundwater 2New software aids fight against nitrates in Florida's groundwater 3Can gulls smell out a good partner? 2Just add water and treat brain cancer 2
Chicken Aortic Smooth Muscle Cells (CAOSMC) (>500,000 cells)...
Canine Chondrocytes (CnC) (500,000 cells)...
B-FABP (FL-132)...
... Lambda Protein Phosphatase ... Mn2+-dependent protein phosphatase with ... threonine and tyrosine residues. ... amino-acid product of the ...
Biology Products: